Werfen to acquire Omixon, expanding its portfolio in transplant diagnostics

• Werfen expects to acquire Omixon, a privately held corporation headquartered in Budapest, Hungary, focused on the development and commercialization of Next Generation Sequencing (NGS) technologies in transplant diagnostics.
• The transaction is expected to be completed during 2024, subject to customary closing conditions.

Barcelona, Spain, May 15, 2024. Werfen announced today that it has agreed to acquire Omixon , a privately held corporation with an innovative portfolio in transplant diagnostics headquartered in?Budapest, Hungary. The acquisition will allow Werfen to expand its portfolio of transplant diagnostics solutions for hospitals and clinical laboratories.

The purchase price is expected to be approximately?US$25 million and will be funded with cash on hand. The acquisition is subject to customary closing conditions.

“One year after the acquisition of Immucor, this announcement reinforces our commitment to continue investing in transplant diagnostics,” said Carlos Pascual , Werfen CEO.

Pascual continued, “Omixon is a perfect fit to expand our transplant business line with a comprehensive NGS portfolio, coupled with strong bioinformatics capabilities and an exciting pipeline of new solutions.”

“This transaction is not expected to impact our fast-deleveraging trend and our solid commitment to the investment grade rating,” said Javier Gomez , Werfen CFO. “Following our prudent financial policy, we are on track to achieve our objective of reducing the financial leverage ratio below 3.0x between the end of the current year and the first quarter of 2025.”

"We are thrilled to join forces with Werfen renowned for its excellence in specialized diagnostics," said Attila Bérces , PhD, Founder and CEO of Omixon. "This partnership presents an exciting opportunity to leverage our respective strengths and resources to further advance transplant diagnostics and make a meaningful impact in the field of transplantation worldwide."